Triple-Negative Breast Cancer

Publication date: January 2018
Source:Surgical Oncology Clinics of North America, Volume 27, Issue 1
Author(s): Lubna N. Chaudhary, K. Hope Wilkinson, Amanda Kong

Teaser

Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer. Clinical research in the neoadjuvant setting is focused on improvement in pathologic complete response rates and outcomes of patients with residual disease.


http://ift.tt/2AD0GD2